{"slug":"swog","tag":"swog","variants":["swog"],"description":"No description yet","count":6,"kinds":{"person":6},"related":[{"slug":"adc","tag":"adc","shared":1},{"slug":"breast","tag":"breast","shared":1},{"slug":"colorectal","tag":"colorectal","shared":1},{"slug":"de-escalation","tag":"de-escalation","shared":1},{"slug":"immunotherapy","tag":"immunotherapy","shared":1},{"slug":"melanoma","tag":"melanoma","shared":1},{"slug":"microbiome","tag":"microbiome","shared":1},{"slug":"myeloma","tag":"myeloma","shared":1},{"slug":"neoadjuvant","tag":"neoadjuvant","shared":1},{"slug":"parp","tag":"parp","shared":1},{"slug":"prostate","tag":"prostate","shared":1},{"slug":"rcc","tag":"rcc","shared":1}],"records":[{"id":"kevin-kalinsky","kind":"person","name":"Kevin Kalinsky","route":"/people/kevin-kalinsky/","tldr":"Led RxPONDER, which showed postmenopausal women with 1-3 positive nodes and low recurrence scores do not need chemotherapy."},{"id":"heinz-josef-lenz","kind":"person","name":"Heinz-Josef Lenz","route":"/people/heinz-josef-lenz/","tldr":"Colorectal oncologist who led CheckMate 142 and co-led CheckMate 8HW, bringing nivolumab plus ipilimumab to MSI-high disease."},{"id":"maha-hussain","kind":"person","name":"Maha Hussain","route":"/people/maha-hussain/","tldr":"Led PROSPER and the PROfound survival analysis, and settled the intermittent hormone therapy question with SWOG 9346."},{"id":"sumanta-pal","kind":"person","name":"Sumanta K. Pal","route":"/people/sumanta-pal/","tldr":"Led SWOG 1500, the first randomised trial to set a standard for papillary kidney cancer, and studies of the microbiome in RCC immunotherapy."},{"id":"sapna-patel","kind":"person","name":"Sapna P. Patel","route":"/people/sapna-patel/","tldr":"Led SWOG S1801, the trial that showed giving pembrolizumab before surgery, not just after, improves outcomes in melanoma."},{"id":"sagar-lonial","kind":"person","name":"Sagar Lonial","route":"/people/sagar-lonial/","tldr":"Led SIRIUS and the DREAMM programme, bringing daratumumab monotherapy and the BCMA ADC belantamab to myeloma."}]}